Form 4: Quest Diagnostics Executive Sells Shares After Exercising Options

A Quest Diagnostics executive, Michael E. Prevoznik, sold a significant number of shares after exercising stock options, according to a recent SEC filing.

Summary

• Michael E. Prevoznik, a Senior Vice President and General Counsel at Quest Diagnostics, exercised stock options to acquire 35,146 shares of common stock at $86.63 per share.
• Following the exercise, Mr. Prevoznik sold 3,009 shares at a weighted average price of $162.2588 and 32,137 shares at a weighted average price of $163.1473.
• After these transactions, Mr. Prevoznik directly owns 38,478 shares and indirectly owns 5,618 shares through a 401(k)/SDCP plan.
• The transactions were executed under a pre-arranged Rule 10b5-1 sales plan.

Sentiment

Score: 5

Explanation: The document reflects a routine executive stock transaction, which is neither particularly positive nor negative.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although these sales were pre-planned.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's future.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation for publicly traded companies.
• The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
• The sale prices are within the normal range for the stock price of Quest Diagnostics.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but the pre-planned nature of the sales mitigates any significant negative impact.

Key Dates

Keywords

Quest Diagnostics, stock options, insider trading, SEC Form 4, executive stock sale, Rule 10b5-1, DGX